METHODS AND PHARMACEUTICAL COMPOSITIONS FOR IMPROVING WOUND HEALING USING CD24

• US 20180221445A1
• Filed: 08/10/2016
• Published: 08/09/2018
• Est. Priority Date: 08/10/2015
• Status: Active Grant

• Current Assignee: Nadir Arber
• Original Assignee: The Medical Research, Infrastructure And Health Services Fund Of The Tel Aviv Medical Center
• Inventors: ARBER, Nadir, SHAPIRA, Shiran, KAZANOV, Dina
• Granted Patent: US 10,639,350 B2
• Time in Patent Office: Days
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: A01K 2227/105 Murine
• CPC Class Codes: A01K 2267/03 Animal model, e.g. for test or diseases
• CPC Class Codes: A61K 38/177 Receptors; Cell surface antigens; Cell surface determinants
• CPC Class Codes: A61K 38/1774 Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61L 15/44 Medicaments
• CPC Class Codes: A61L 2300/252 Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: C12N 2740/15043 viral genome or elements thereof as genetic vector

Abstract

Provided are methods of improving wound healing in a subject by administering a therapeutically effective amount of CD24. Also provided are pharmaceutical compositions which comprise CD24 being in a formulation with a surfactant and a pharmaceutically acceptable carrier.

Claims

1. A method of improving wound healing in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of CD24, thereby improving wound healing in the subject.

3. The method of claim 1, wherein said CD24 is injected to the subject.

4. The method of claim 1, wherein said CD24 is applied directly on a wounded area of the subject.

5. The method of claim 4, wherein said CD24 is applied by dropping a pharmaceutical composition comprising said CD24 on said wounded area of the subject.

6. The method of claim 1, wherein said CD24 is comprised in a medical dressing.

7. The method of claim 6, wherein said CD24 is soaked or impregnated in said medical dressing.

8. The method of claim 1, wherein said administering said CD24 is by in vivo gene therapy.

9. The method of claim 1, wherein said CD24 is comprised in a pharmaceutical composition.

10. The method of claim 9, wherein said CD24 is formulated with a surfactant in said pharmaceutical composition.

11. The method of claim 10, wherein said surfactant is an ionic surfactant.

12. The method of claim 10, wherein said surfactant is a non-ionic surfactant.

16. The method of claim 1 wherein said CD24 is comprised in a lentiviral construct.

17. The method of claim 9, wherein a concentration of said CD24 in said pharmaceutical composition is between 1% to 10% (volume/volume) of a purified CD24 solution.

18. The method of claim 1, wherein said CD24 is glycosylated.

19. The method of claim 1, wherein said CD24 comprises a native glycosylation pattern.

20. The method of claim 1, wherein said CD24 is non-glycosylated.

21. The method of claim 1, wherein said CD24 is soluble.

22. The method of claim 1, wherein said CD24 is non-soluble.

23. The method of claim 1, wherein said CD24 is conjugated to a lipid moiety.

24. The method of claim 9, wherein said pharmaceutical composition is suitable for topical application.

25. The method of claim 24, wherein said pharmaceutical composition is comprised in an emulsion carrier, a cream, an ointment, an aqueous solution, a lotion or an aerosol.

2. A method of improving wound healing in a subject in need thereof, the method comprising topically administering to a wounded area of the subject a therapeutically effective amount of CD24, thereby improving the wound healing in the subject.

13. A pharmaceutical composition suitable for topical administration, comprising CD24 being in a formulation with a surfactant and a pharmaceutically acceptable carrier.

14. The pharmaceutical composition of claim 13, wherein said surfactant is an ionic surfactant.

15. The pharmaceutical composition of claim 13, wherein said surfactant is a non-ionic surfactant.

26. The pharmaceutical composition of claim 13, wherein said CD24 is comprised in a lentiviral construct.

27. The pharmaceutical composition of claim 13, wherein a concentration of said CD24 in said pharmaceutical composition is between 1% to 10% (volume/volume) of a purified CD24 solution.

28. The pharmaceutical composition of claim 13, wherein said CD24 is glycosylated.

29. The pharmaceutical composition of claim 13, wherein said CD24 comprises a native glycosylation pattern.

30. The pharmaceutical composition of claim 13, wherein said CD24 is soluble.